Welcome to our dedicated page for Curative Biotechnology news (Ticker: CUBTD), a resource for investors and traders seeking the latest updates and insights on Curative Biotechnology stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Curative Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Curative Biotechnology's position in the market.
Curative Biotechnology (CUBT, temporarily CUBTD) executed a 1-for-150 reverse stock split effective March 23, 2026, reducing outstanding shares from ~1.02 billion to ~6.8 million and DTC-eligible shares from ~266.8 million to ~1.78 million. The company's ticker will show as CUBTD for 20 trading days.
Curative plans manufacturing to begin mid-April 2026, received a U.S. manufacturer proposal for sterile metformin ophthalmic drops, intends a Phase 1 NIH CRADA human study for dry AMD, and will pursue an OTCQB uplisting after a manufacturing agreement.